Patents Assigned to Valeant Pharmaceuticals International
-
Patent number: 9949877Abstract: A laser system including: a laser source operable to emit a first laser beam having a first operating wavelength and a second laser beam having a second operating wavelength; a fiber optic cable to guide and homogenize the first and second laser beams; an expander to increase the diameter of the first and second laser beams; a cylinder to guide the first and second laser beams and limit respective diameters of the first and second laser beams, wherein the cylinder is positioned after the expander on an optical path of the laser beam; a first optical system to collimate the first and second laser beams, wherein the optical system is positioned after the cylinder on the optical path of the first and second laser beams; a spot-size selector comprising a plurality of apertures, wherein the spot-size selector is positioned after the first optical system on the optical path of the first and second laser beams; and a second optical system to focus the first and second laser beams on a tissue of the patient.Type: GrantFiled: October 1, 2015Date of Patent: April 24, 2018Assignee: Valeant Pharmaceuticals International, Inc.Inventors: Valery Rubinchik, Charles Richard Kjellbotn, Greg Heacock, Louise Culham, Wes A. Williams
-
Patent number: 9655829Abstract: Disclosed herein are teeth whitening compositions generally including an oxidizing agent, and an activating agent that has an emission wavelength between about 400 nm and about 570 nm. Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.Type: GrantFiled: January 26, 2016Date of Patent: May 23, 2017Assignee: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.Inventors: Nikolaos Loupis, Remigio Piergallini
-
Patent number: 9226917Abstract: The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.Type: GrantFiled: December 16, 2009Date of Patent: January 5, 2016Assignee: Valeant Pharmaceuticals International, Inc.Inventors: H. Andrew Strong, Yong Hao
-
Patent number: 9211214Abstract: A laser system including: a laser source operable to emit a first and a second laser beam having first and second operating wavelengths, respectively; a fiber optic cable to guide and homogenize the laser beams; an expander to increase the diameter of the laser beams; a cylinder to guide the laser beams and limit respective diameters of the first and second laser beams, wherein the cylinder is positioned after the expander on an optical path of the laser beam; a first optical system to collimate the laser beams, wherein the optical system is positioned after the cylinder on the optical path of the laser beams; a spot-size selector comprising a plurality of apertures, wherein the spot-size selector is positioned after the first optical system on the optical path of the laser beams; and a second optical system to focus the laser beams on a tissue of the patient.Type: GrantFiled: March 21, 2012Date of Patent: December 15, 2015Assignee: Valeant Pharmaceuticals International, IncInventors: Valery Rubinchik, Charles Richard Kjellbotn, Greg Heacock, Louise Culham, Wes A. Williams
-
Patent number: 8993593Abstract: This invention provides a compound of formula A The compound provided herein can affect the opening of, or otherwise modulate, voltage-gated potassium channels. The compound provided herein is useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.Type: GrantFiled: February 1, 2010Date of Patent: March 31, 2015Assignee: Valeant Pharmaceuticals InternationalInventors: Jean-Michel Vernier, Martha Alicia De La Rosa, Huanming Chen, Jim Zhen Wu, Gary Lee Larson, Ian Wayne Cheney
-
Patent number: 8859618Abstract: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.Type: GrantFiled: September 19, 2013Date of Patent: October 14, 2014Assignee: Valeant Pharmaceuticals InternationalInventors: Irwin Palefsky, Ni'Kita Wilson
-
Patent number: 8852629Abstract: Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.Type: GrantFiled: June 19, 2009Date of Patent: October 7, 2014Assignee: Valeant Pharmaceuticals International, Inc.Inventors: Ronald Erwin Boch, Dev Mitra Ranji Singh, Iman Karmadi
-
Patent number: 8722929Abstract: This invention provides compounds of formula A and formula B which are modulators of potassium ion channels and are useful for the treatment of seizure disorders.Type: GrantFiled: October 10, 2007Date of Patent: May 13, 2014Assignee: Valeant Pharmaceuticals InternationalInventors: Jean-Michel Vernier, Jianlan Song, Huanming Chen, Zhi Hong
-
Publication number: 20140105832Abstract: Disclosed herein are teeth whitening compositions generally including an oxidizing agent, and an activating agent that has an emission wavelength between about 400 nm and about 570 nm. Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.Type: ApplicationFiled: September 4, 2013Publication date: April 17, 2014Applicant: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.Inventors: Nikolaos LOUPIS, Remigio PIERGALLINI
-
Publication number: 20140023610Abstract: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.Type: ApplicationFiled: September 19, 2013Publication date: January 23, 2014Applicant: VALEANT PHARMACEUTICALS INTERNATIONALInventors: Irwin PALEFSKY, Ni'Kita WILSON
-
Patent number: 8563566Abstract: This invention provided compounds of formula I where W and Z are, independently, CH or N, and where other substituents are defined herein. Such compounds are potassium channel modulators. The invention also provides a composition comprising a pharmaceutically acceptable carrier or excipient and at least one of the following: a pharmaceutically effective amount of a compound of formula I; a pharmaceutically acceptable salt of a compound of formula I; a pharmaceutically acceptable ester of a compound of formula I. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt or ester or solvate thereof.Type: GrantFiled: July 28, 2008Date of Patent: October 22, 2013Assignee: Valeant Pharmaceuticals InternationalInventors: Jean-Michel Vernier, Martha De la Rosa
-
Patent number: 8563604Abstract: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.Type: GrantFiled: September 30, 2008Date of Patent: October 22, 2013Assignee: Valeant Pharmaceuticals InternationalInventors: Irwin Palefsky, Ni'Kita Wilson
-
Patent number: 8492588Abstract: The present invention relates to benzyloxyanilide derivatives having the following structural formula: The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.Type: GrantFiled: May 29, 2012Date of Patent: July 23, 2013Assignee: Valeant Pharmaceuticals InternationalInventors: Jim Zhen Wu, Jean-Michel Vernier, Huanming Chen, Jianlan Song
-
Patent number: 8367684Abstract: This invention provides potassium channel modulators which are compounds of formula I where at least one of W and Z is N; where the moiety is one of Groups A or B below A where Ar is a 1,2-fused, six membered ring aromatic group, bearing substituents R1 and R2 as defined below, and containing zero or one ring nitrogen atom; and where other substituents are defined herein. The invention also provides a composition comprising a pharmaceutically acceptable carrier and at least one of the following: i) a pharmaceutically effective amount of a compound of formula I and ii) a pharmaceutically acceptable salt, ester, or prodrug thereof. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt, ester, or prodrug thereof.Type: GrantFiled: June 12, 2008Date of Patent: February 5, 2013Assignee: Valeant Pharmaceuticals InternationalInventors: Jean-Michel Vernier, Samedy Ouk, Martha A. De La Rosa
-
Patent number: 8338487Abstract: This invention provides compounds of formula I where Ar1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR3R4 group is situated ortho to the NHC(?X) group; n=1 or 2; X=O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.Type: GrantFiled: April 29, 2011Date of Patent: December 25, 2012Assignee: Valeant Pharmaceuticals International, Inc.Inventors: Huanming Chen, Jean-Michel Vernier
-
Patent number: 8293911Abstract: This invention provides a compound of formula IA where X?O or S; Y is O or S; q=1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.Type: GrantFiled: August 22, 2007Date of Patent: October 23, 2012Assignee: Valeant Pharmaceuticals InternationalInventors: Jean-Michel Vernier, Martha Alicia De La Rosa, Huanming Chen, Jim Zhen Wu, Gary Lee Larson, Ian Wayne Cheney
-
Patent number: 8211918Abstract: This invention provides compounds of formula I where the dashed line represents an optional double bond; where R1 is phenyl, naphthyl, pyridyl, pyrimidyl, pyrrolyl, imidazolyl, pyrazyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, optionally substituted, and other substituents are defined herein. Such compounds are potassium channel modulators.Type: GrantFiled: August 13, 2010Date of Patent: July 3, 2012Assignee: Valeant Pharmaceuticals InternationalInventors: Jean-Michel Vernier, Huanming Chen, Jianlan Song
-
Patent number: 8188314Abstract: The present invention relates to benzyloxyanilide derivatives having the following structural formula: The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.Type: GrantFiled: June 24, 2009Date of Patent: May 29, 2012Assignee: Valeant Pharmaceuticals InternationalInventors: Jim Zhen Wu, Jean-Michel Vernier, Huanming Chen, Jianlan Song
-
Patent number: 8067452Abstract: This invention provides compounds of Formula I which are inhibitors of Chk2 and are useful as a radiation protection agents in anticancer radiotherapy. A method of modulating Chk2 in vitro includes treating a substrate with Chk2 in the presence of compounds of formula I. A method of making a compound of formula I includes: a) forming a biaryl amine having an amino (NH2) group; b) converting the amino group to an isothiocyanate group; c) adding a cyanoacetamide to the isothiocyanate group to form a thioamide adduct; d) cyclizing the thioamide adduct to form an isothiazole having a cyano group; and e) adding an amine to the cyano group to form a carboxamidine group.Type: GrantFiled: June 20, 2008Date of Patent: November 29, 2011Assignee: Valeant Pharmaceuticals InternationalInventors: Jim Zhen Wu, Huanming Chen
-
Patent number: 8030518Abstract: This invention is directed to compounds of formula I, where G is —O—, —S—, —C(g1)(g2)-, or —NH—, and n=1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is seizure disorders.Type: GrantFiled: November 28, 2007Date of Patent: October 4, 2011Assignee: Valeant Pharmaceuticals InternationalInventors: Huanming Chen, Jianlan Song, Jean-Michel Vernier, Jim Zhen Wu